Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H27ClO3 |
Molecular Weight | 374.901 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@]1([H])[C@@]3(C)C(=CC2=O)C(Cl)=C[C@@]4([H])[C@]5([H])CC[C@](O)(C(C)=O)[C@@]5(C)CC[C@]34[H]
InChI
InChIKey=DUSHUSLJJMDGTE-ZJPMUUANSA-N
InChI=1S/C22H27ClO3/c1-11(24)22(26)7-5-14-12-9-18(23)17-10-19(25)13-8-16(13)21(17,3)15(12)4-6-20(14,22)2/h9-10,12-16,26H,4-8H2,1-3H3/t12-,13+,14-,15-,16-,20-,21-,22-/m0/s1
Molecular Formula | C22H27ClO3 |
Molecular Weight | 374.901 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.medbroadcast.com/drug/getdrug/cyproteroneCurator's Comment: description was created based on several sources, including:
https://en.wikipedia.org/wiki/Cyproterone
Sources: http://www.medbroadcast.com/drug/getdrug/cyproterone
Curator's Comment: description was created based on several sources, including:
https://en.wikipedia.org/wiki/Cyproterone
Cyproterone belongs to a group of medications known as steroidal antiandrogens. It suppresses testosterone and its metabolites. It has approximately three-fold lower potency as an antagonist of the androgen receptor relative to cyproterone acetate. Cyproterone acetate is used to treat advanced prostate cancer and acne.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Estradiol 17α-dehydrogenase Sources: https://www.ncbi.nlm.nih.gov/pubmed/4125095 |
|||
Target ID: CHEMBL2363075 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4125095 |
|||
Target ID: P49699 Gene ID: NA Gene Symbol: AR Target Organism: Oryctolagus cuniculus (Rabbit) Sources: https://www.ncbi.nlm.nih.gov/pubmed/165597 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Systemic sclerosis following anti-androgenic treatment for prostatic adenocarcinoma. | 1993 Mar |
|
Glucocorticoid and sex hormones as activating or modulating factors for expression of Cyp2b-9 and Cyp2b-10 in the mouse liver and hepatocytes. | 1995 May 10 |
|
Skin ulcers in a young woman on low-dose estrogen-combination pill. | 1997 Apr |
|
Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. | 2001 Oct 27 |
|
Recurrent pulmonary embolism in an elderly patient with Cushing's syndrome, adrenocortical adenoma, pheochromocytoma and prostate adenocarcinoma. | 2004 Jul |
|
Suspected propranolol-induced delirium. | 2004 Sep |
|
Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. | 2004 Sep |
|
Modulation of steroidogenic gene expression and hormone production of H295R cells by pharmaceuticals and other environmentally active compounds. | 2007 Dec 1 |
|
Aurintricarboxylic acid inhibits influenza virus neuraminidase. | 2009 Feb |
|
Ciproterone effect on compulsive masturbation in a frontotemporal dementia patient. | 2010 Summer |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24053431
200 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4125095
The 'uptake' of the anti-androgen cyproterone by human prostate slices was measured in two hyperplastic and two adenocarcinomatous glands. Samples of tissue slices of similar weight from the two hyperplastic glands were superfused with medium containing increasing amounts of cyproterone. There was no variation in the 'uptake' of cyproterone within the concentration range in the medium from 2.63 to 17.49 umol/litre.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:31:33 GMT 2023
by
admin
on
Fri Dec 15 16:31:33 GMT 2023
|
Record UNII |
E61Q31EK2F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
G03HB01
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
||
|
WHO-VATC |
QG03HA01
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
||
|
NCI_THESAURUS |
C146993
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
||
|
WHO-VATC |
QG03HB01
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
||
|
WHO-ATC |
G03HA01
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
||
|
LIVERTOX |
NBK548024
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2050
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
m4041
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | Merck Index | ||
|
C407
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
50742
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
758636
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
CHEMBL139835
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
5284537
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
SUB06877MIG
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
DTXSID3022873
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
2098-66-0
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
E61Q31EK2F
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
CYPROTERONE
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
D003534
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | |||
|
3014
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000083989
Created by
admin on Fri Dec 15 16:31:33 GMT 2023 , Edited by admin on Fri Dec 15 16:31:33 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||